DPP4 and Parkinson disease: The focus of the current study is to evaluate the potential of dipeptidyl peptidase-4 (DPP-4) inhibitors, also known as the gliptin drug class, as a new treatment strategy for PD, since standard PD pharmacotherapy is limited by a progressive loss of efficacy and development of adverse effects with time.